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ABSTRACT
Objective: Uncertainty about the value of antiretroviral therapy (ARV)
adherence interventions may be a barrier to implementation and evalua-
tion. Our objective is to estimate the minimum effectiveness required for
ARV adherence interventions to deliver acceptable value.
Methods: We used a validated HIV computer simulation to estimate the
impact of ARV adherence interventions on incremental costs and life
expectancy. Across a wide range of intervention costs ($1000–10,000, one
time or per year), we estimated the smallest effect size compatible with
acceptable value (incremental cost-effective ratio $100,000 per life-
year). Effect sizes were measured using relative risk (RR) and absolute risk
reduction (ARR), and these metrics were applied to nonadherence and
nonadherence risk factors. Costs were estimated from a societal perspec-
tive ($2003) discounted at 3%.
Results: To give acceptable value, a one-time $1000 intervention must
reduce ARV nonadherence by RR  0.82 (ARR  0.04) for moderately
nonadherent patients (20% of ARV doses missed) and RR  0.90
(ARR  0.05) for severely nonadherent patients (50% of ARV doses
missed). A one-time $5000 intervention has an unacceptable value regard-
less of effect size for moderately nonadherent patients, and must reduce
ARV nonadherence by RR  0.31 (ARR  0.69) for severely nonadherent
patients. Interventions aimed at behavioral risk factors (e.g., unhealthy
alcohol use) may confer acceptable value (e.g., if $2000 and effect
RR  0.71 [ARR  0.29]).
Conclusions: ARV adherence interventions with plausible effect sizes may
offer favorable value if they cost <$5000 one time or per year. ARV
adherence interventions with a favorable value should become more inte-
gral components of HIV care.
Keywords: adherence, AIDS, cost-effectiveness analysis, health services.
Introduction
Nonadherence with antiretroviral therapy (ARV) remains preva-
lent even though newer regimens have fewer side effects and
lower pill burdens. Pharmacy reﬁll records from a national health
system suggest at least 37% of doses of all regimens are not taken
as directed, and at least 33% of doses of efavirenz-based regi-
mens are not taken as directed, even though they are noted for
their tolerability [1]. At the same time, ARV nonadherence is a
major cause of preventable morbidity and mortality among HIV-
infected persons. Failing to suppress viral replication leads to
higher rates of AIDS-deﬁning events and deaths, and in the long
term may induce drug-resistant viral strains. Indeed, observed
levels of nonadherence would be expected to shorten life expect-
ancy by as much as 3.9 to 7.0 years [2] or 2.9 to 5.9 quality-
adjusted life-years [3].
Because improving ARV adherence has a great potential to
lower morbidity and mortality in HIV-infected persons, it is
important to evaluate interventions that aim to improve adher-
ence. Adherence interventions (e.g., directly observed therapy),
however, may be expensive, and value is becoming more impor-
tant as an evaluation criterion. A formidable barrier to evaluat-
ing nonadherence interventions is the practicality of
implementing an effective intervention because of its costs. In
other words, an intervention must demonstrate satisfactory
efﬁcacy (effect size) to justify the cost associated with its imple-
mentation. If not, there may be uncertainty regarding how much
of an improvement in nonadherence is necessary (i.e., the
minimum effect size required) for the cost of the intervention to
represent acceptable value.
A rigorous prior report has projected the cost-effectiveness of
nonadherence interventions [3]. Unfortunately, this study may
not always be applicable to the design of intervention trials for a
number of reasons. First, it did not explicitly consider how
reductions in nonadherence might increase medication expendi-
tures, making nonadherence interventions seem more economi-
cally attractive than they really are. Second, minimum effect sizes
were expressed exclusively in terms of short-term changes in viral
load rather than in terms of changes in nonadherence. Nonad-
herence may have positive effects that are not mediated through
short-term viral load changes (e.g., lessening the likelihood of
drug resistance accrual) [4] and is increasingly feasible to
measure with electronic medical records (EMRs) [5,6]. Finally,
this study did not consider adherence interventions directed at
risk factors for nonadherence that are particularly common in
HIV populations (e.g., alcohol abuse, drug abuse, and psychiatric
comorbidity) [7], and these risk factors may represent important
intervention opportunities.
Because it is uncertain how much of an effect to require from
adherence interventions in clinical trials, and it is uncertain when
an adherence intervention merits incorporation into clinical prac-
tice, we have used a validated computer simulation of HIV
infection [8] to estimate how much of a decrease in nonadherence
would be required for an intervention to deliver acceptable value.
In contrast to prior analyses, our analysis explicitly considers
downstream costs from increased medication expenditures and
interventions aimed at behavioral risk factors.
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Methods
We describe, ﬁrst, our computer simulation of HIV progression;
second, the types of nonadherence interventions that we use this
simulation to evaluate; third, the target populations of these
analyses; and fourth, our criterion for acceptable value and our
analytical perspective.
Computer Simulation
We have developed a computer simulation of HIV progression
that was developed “from the ground up” in the ARV era (Fig. 1).
It differs from computer simulations used in prior simulations of
nonadherence interventions [3] because it incorporates biologic
processes that underlie the eventual decreased effectiveness of
ARV (genotypic resistance accumulation and poor adherence).
For this reason, it is not only able to estimate the short-term
mortality impact of changes in ARV nonadherence because of
improvements in viral load and CD4 count trajectories, but it is
also able to estimate the long-term mortality impact of changes in
ARV nonadherence because of improvements in drug resistance
accrual risk. For example, it may be intuitively unclear whether
increasing adherence from 50% to 62% would beneﬁt a patient
because an improvement in short-term outcomes from greater
viral load suppression may be overshadowed by a worsening in
long-term outcomes because of increased resistance accumula-
tion. The simulation can weigh this trade-off explicitly, and can
estimate whether this change in adherence would be favorable,
together with the magnitude of its effect. Furthermore, the simu-
lation is able to estimate the incremental costs that arise when
more ARV doses are taken as a result of improving adherence.
The simulation can assign otherwise similar patient cohorts
to different interventions and compare the impact of these inter-
ventions on designated outcomes. Because the simulation is
probabilistic, it is able to represent much of the heterogeneity of
actual patient populations (e.g., clinical events, such as deaths,
may or may not happen within any particular time interval, and
their probability of occurrence is based on known predictors). Its
design is described in more detail elsewhere [8–10]. Its data
inputs have not been changed from those used that are reported
elsewhere because these resulted in the best calibration and vali-
dation of the model (Table 1). This model has closely reproduced
Kaplan–Meier curves of time to treatment failure and survival
among 3545 ARV-naive patients [8], has yielded 3-year mortality
estimates similar to those from a 12,574 patient cohort that was
distinct from the derivation cohort [8], and has replicated and
explained clinically observed heterogeneity in the relationship of
ARV adherence to resistance mutation accumulation [9,10].
Interventions
The advent of EMR systems makes it increasingly feasible to
identify nonadherent patients during routine visits, and to screen
them for risk factors. We reasoned that as health information
technology becomes more sophisticated, patients may be increas-
ingly targeted for nonadherence interventions if 1) they are
thought to have suboptimal adherence based on validated algo-
rithms that estimate adherence from pharmacy reﬁll records,
and/or 2) they have identiﬁable risk factors for nonadherence
based on the results of common screening tests that are entered
into the EMR system. Correspondingly, we analyzed two catego-
ries of hypothetical interventions; ﬁrst, those that decreased the
likelihood of antiretroviral nonadherence, and second, those that
decreased the likelihood of behaviors that are known to be
important modiﬁable risk factors for nonadherence (unhealthy
alcohol use [incorporating hazardous alcohol consumption, as
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Figure 1 Schematic of computer simulation.The
simulation is able to consider not only the shorter
term impact of reducing combination antiretrovi-
ral therapy (ARV) nonadherence on improving
viral load and CD4 count (particularly important
for individuals with severe nonadherence), but also
the longer term impact of reduced nonadherence
on loweringARV resistance accumulation (particu-
larly important for individuals with moderate
nonadherence).
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well as harmful alcohol use, alcohol abuse, and alcohol depen-
dence] [15], drug dependence, and depression). Addressing these
risk factors may be a complementary strategy to addressing
nonadherence itself because clinical data suggest that the impact
on antiretroviral nonadherence is greatest for unhealthy alcohol
use (relative risk [RR] for nonadherence: 2.7 for “heavy frequent
alcohol use” [7] as well as for hazardous alcohol use [14]) and
somewhat lower for drug abuse (RR for nonadherence: 1.6–2.3,
depending upon drug type) or depression (RR for nonadherence:
1.7).
We chose RR as an intervention outcome metric because it
was applicable across a wide range of targeted behaviors and risk
factors (i.e., nonadherence, as well as risk factors for nonadher-
ence), and because it scales well with different levels of baseline
nonadherence. For RRs between 0 and 1, larger RRs correspond
to lesser effects, whereas smaller RRs correspond to greater
effects. In addition, we report outcomes using the alternate
metric of absolute risk reduction (ARR). In contrast to RRs,
larger ARRs correspond to greater effects, whereas smaller ARRs
correspond to lesser effects. Note that ARR does not scale with
baseline nonadherence, and therefore, the maximum ARR is
dependent upon the baseline nonadherence (e.g., if baseline non-
adherence is 0.20, then the maximum ARR is 0.20).
To work through an illustrative example, for patients with a
baseline nonadherence of 0.20, an intervention with an ARR of
0.20 would lower the proportion of nonadherence from 0.20 to
0, which would correspond to an RR of 0. For patients with 0.50
nonadherence at baseline, an intervention with an ARR of 0.20
would lower the proportion of nonadherence from 0.50 to 0.30,
corresponding to an RR of 0.6. Because alcohol increases the RR
of nonadherence by 2.7, an alcohol intervention that was com-
pletely effective would lower the proportion of nonadherence
from its baseline value to that baseline value divided by 2.7.
Analogous calculations apply to drug use and depression
interventions.
Interventions may have variable frequencies and durations,
ranging from one-time events such as a brief motivational inter-
vention to recurrent interventions such as a directly observed
therapy. For this reason, we analyzed alternate scenarios regard-
ing intervention frequencies and duration of effect: 1) an inter-
vention that had a one-time cost and a short-term effect (6
months, i.e., a typical follow-up period in a clinical trial), and 2)
an intervention that had a recurrent, yearly cost and an enduring
effect. In sensitivity analyses, we analyzed the most optimistic
scenario in which an intervention had a one-time cost but had a
persistent effect.
Target Population
We considered adherence interventions for patients with HIV
infection who are already prescribed ARV and who are known to
have adherence difﬁculties (e.g., pharmacy reﬁll records suggest-
ing that adherence is suboptimal). We speciﬁed two separate
populations who may be targeted for adherence interventions:
persons with moderate nonadherence (deﬁned as not taking 20%
of prescribed ARV doses as directed) and persons with severe
nonadherence (deﬁned as not taking 50% of prescribed ARV
doses as directed). Patients with moderate nonadherence may be
suitable targets for adherence improvement because they are at
particularly high risk of developing resistance mutations because
the inverse U-shaped relationship between adherence and resis-
tance accumulation peaks around this level [4,9], and because
higher adherence may be required to maximize viral load sup-
pression [16,17]. Patients with severe nonadherence may be suit-
Table 1 Inputs in computer simulation of HIV progression for patients on combination antiretroviral therapy (ARV).All were assumed to be 40 years
old, have a pre-ARV CD4 count of 350 cells/ul, and have a pre-ARV viral load of 100,000 copies/ml
Parameter Estimate(s) Reference
Adherence impact on
ARV viral load decrement Increases linearly (0–2.9 log unit decrease as nonadherence increases from 0% to
100%)
[1,9]
ARV resistance accrual Varies in U-shaped relationship (threefold increase then decrease as adherence
increases from 0% to 100%)
[9]
Log viral load impact on
ARV CD4 elevation Increases linearly with log viral load decrement (70 cells/ul increase as log viral
load decrement increases from 0 log units to 2.9 log units)
[9]
ARV resistance accrual Increases nonlinearly (up to 30-fold increase as resistance develops to all ARV
drugs)
[9]
HIV-related mortality Increases nonlinearly (as much as from 0.09 to 0.18 as log viral load increases from
<3.5 to >5.5)
[8]
CD4 impact on
HIV-related mortality Decreases nonlinearly (as much as from 0.18 to <0.01 as CD4 increases from <50
cells/ul to >500 cells/ul)
[8]
ARV resistance impact on
ARV viral load decrement Decreases linearly (2.9 log unit increase as proportion of resistant drugs in ARV
regimen increases to 1)
[9]
Costs (yearly)
ARV $10,300 [3]
Non-ARV HIV care Decreases nonlinearly with CD4 count (from $6400 with CD4 < 50 to $28,000 for
CD4 > 200)
[11]
Utility
Off-ARV utility Increases nonlinearly with CD4 count (from 0.79 units with CD4 < 50 to 0.94
units for CD4 > 200
[12]
Utility decrement from ARV side effects 0.08 units [13]
Proportion on ARV with side effects 67% [13]
Behavioral risk factor impact on nonadherence (RR)
Unhealthy alcohol use RR 2.7 [7,14]
Drug dependence RR 2.0 [7]
Depression RR 1.7 [7]
RR, relative risk.
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able targets for adherence improvement because they have
poorer viral load and CD4 responses to ARV [1,18], which
increases the risk of AIDS and HIV-related death.
All patients in our target population had CD4 counts of 350
cells/ul, pre-ARV viral loads and 100,000/mL, and ages of 40
years because these are similar to the pre-ARV-initiation charac-
teristics of multiple clinical cohorts, and facilitate comparisons
with our previous analyses; however, we varied these character-
istics in sensitivity analyses.
Criterion for Acceptable Value
Published reports suggest that individuals in the United States are
willing to pay $100,000 to obtain an additional life-year or
quality-adjusted life-year of beneﬁt from medical care, and cor-
respondingly, that $100,000 per life-year or per quality-adjusted
life-year may be thought of as a lower bound for acceptable value
[19]. Accordingly, in our base case, we used our computer simu-
lation to estimate the smallest intervention effect size that deliv-
ered 1 life-year per $100,000 spent, and therefore, was consistent
with acceptable value. In sensitivity analyses, we used the simu-
lation to estimate the smallest intervention effect size that deliv-
ered 1 quality-adjusted life-year per $100,000 spent.
Analytical Perspective
We inﬂated all costs to $2003 using the consumer price index for
all goods and services [20]. We used a societal perspective for our
analysis as recommended by the Panel on Cost-Effectiveness in
Health Care [21], meaning that we treated costs identically
regardless of whether they were incurred by payers or patients, or
whether they accrued from inpatient expenses, outpatient
expenses, or drugs. Also, as recommended by the Panel on Cost-
Effectiveness in Health Care, we used a discount rate of 3%. A
discount rate reﬂects the idea that costs and beneﬁts that accrue
in the future are valued less than costs and beneﬁts that accrue
today, even after adjusting for inﬂation. We followed all patients
until death from HIV-related or non-HIV-related causes, and
therefore assumed an indeﬁnite time horizon. Each cohort simu-
lation was run with 1,000,000 hypothetical patients.
Results
We used the computer simulation to estimate the impact of
hypothetical nonadherence interventions on life expectancy and
costs. By comparing the increase in life expectancy with the
increase in costs (from the intervention itself, as well as from the
downstream costs of the intervention such as increased medica-
tion costs), we were able to estimate the incremental cost-
effectiveness of the nonadherence intervention. Consequently, we
were able to estimate the minimum effect size necessary for an
intervention to offer acceptable value at a particular cost.
We ﬁrst describe our results analyzing the value of interven-
tions directly acting on nonadherence, followed by our results
analyzing the value of interventions acting on particularly impor-
tant risk factors for nonadherence (unhealthy alcohol use, drug
dependence, and depression).
Nonadherence Interventions
A one-time nonadherence intervention costing $1000 could offer
favorable value with a relatively small effect size of RR  0.82
(ARR  0.04) for 20% baseline nonadherence and RR  0.90
(ARR  0.05) for 50% baseline nonadherence. As the adherence
intervention became more expensive, however, it was less likely
to offer a favorable value (Fig. 2). Even when the nonadherence
intervention was assumed to be completely effective, it could not
offer favorable value if it costs more than $4500 for patients with
20% baseline nonadherence, or if it costs more than $6500 for
patients with 50% baseline nonadherence.
When nonadherence interventions were assumed to have sus-
tained costs and effects (Table 2), smaller effect sizes were com-
patible with acceptable value. A sustained nonadherence
intervention costing $1000 annually could offer a favorable value
with effect sizes of RR  0.87 (ARR  0.03) for patients with
20% baseline nonadherence and effect sizes of RR  0.95
(ARR  0.03) for patients with 50% baseline nonadherence. As
the sustained adherence intervention became more expensive, it
was less likely to offer favorable value. Even when the sustained
nonadherence intervention was assumed to have complete,
enduring effectiveness, it could not offer favorable value if it costs
more than $7000 annually for patients with 20% baseline non-
adherence, or if it costs more than approximately $13,000 for
patients wth 50% baseline nonadherence.
The minimum effect size did not vary linearly with interven-
tion costs because a substantial portion of the incremental costs
of the nonadherence intervention did not arise from the intrinsic
cost of the intervention, but rather arose from increased antiret-
roviral expenditures, particularly for intervention costs below
$10,000 (Fig. 3).
Risk Factor Interventions
For nonadherent patients who screen positive for unhealthy
alcohol consumption, a one-time unhealthy alcohol use interven-
tion costing $1000 could offer favorable value with a moderate
effect size of RR  0.74 (ARR  0.26) for unhealthy alcohol use
persisting, with 50% baseline nonadherence. As the alcohol
intervention became more expensive, however, it was less likely
to offer favorable value (Table 3). Even when the alcohol inter-
vention was assumed to be completely effective, it could not offer
favorable value if it costs more than $4300 for patients with 50%
baseline nonadherence. Results for continuous rather than one-
time interventions showed that somewhat higher costs were com-
patible with acceptable value (for example, $6400 vs. $4300 for
a completely effective alcohol intervention, continuous vs. one
time). Results for patients with lower baseline nonadherence
(20% rather than 50%) suggested that lower costs are required
for acceptable value (for example, $3600 vs. $4300 for a
completely effective alcohol intervention, 20% vs. 50% baseline
nonadherence).
Results for drug abuse and depression interventions in non-
adherent patients who screen positive were generally similar to
results for alcohol interventions, except that achieving the
acceptable value required larger effect sizes (Tables 4 and 5). A
one-time drug abuse intervention costing $1000 required a sub-
stantial effect size to offer favorable value (RR  0.59
[ARR  0.41] with 50% baseline nonadherence). Even when the
drug abuse intervention was assumed to be completely effective,
it could not offer favorable value if it costs more than $3100 for
patients with 50% baseline nonadherence. Results for depression
interventions differed little from results for drug abuse interven-
tions, in accordance with the similar assumptions regarding their
impact on nonadherence that were used as inputs to the model.
Sensitivity Analyses
Our results varied greatly with the presumed duration of effect
of the nonadherence interventions. When we assumed that the
effect of an adherence intervention persisted beyond its duration,
small effect sizes (RR  0.91 [ARR  0.02] for adherence
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interventions; RR  0.77 [ARR  0.05] for risk factor interven-
tions) delivered acceptable value even for expensive interventions
(one-time cost of $10,000).
Discussion
Our results suggest that nonadherence interventions with small
effects (e.g., RR as high as 0.95 or ARR as small as 0.03) could
represent acceptable value if they cost approximately $1000 per
year or less (i.e., the approximate cost of alarms or automated
medication dispensers) [3]. Interventions with larger effects (RR
less than 0.50 or ARR greater than 0.10) could often represent
acceptable value if they cost approximately $5000 per year or
less. For example, because directly observed therapy is likely to
reduce nonadherence by an ARR of at least 0.12 in injection
drug-using populations [22] and its approximate annual cost is
$5000 (for 5 days per week directly observed therapy with one
contact daily [3]), it has the potential to offer favorable value. As
intervention costs approach $10,000 per year (i.e., the approxi-
mate cost of 7 days per week directly observed therapy, or
directly observed therapy with two contacts daily), effects would
need to be implausibly large to represent acceptable value. It is
important to note that directly observed therapies [22–24],
voucher reinforcements [25], and behavioral interventions are
potential candidates for delivering acceptable value.
Adherence interventions could have a substantial value
regardless of whether they were aimed at patients with moderate
nonadherence (20% of doses not taken as directed) or severe
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Figure 2 Adherence intervention effects and costs
compatible with acceptable value ($100,000/
quality-adjusted life-year), stratiﬁed by baseline non-
adherence and persistence of the intervention.
Interventions aimed at severely nonadherent
patients (50% doses taken as directed) generally
confer higher value than interventions aimed at
moderately adherent patients (20% taken as
directed), even though improving the adherence of
severely nonadherent patients may lead to more
rapid accumulation of resistance mutations. ARR,
absolute risk reduction; RR, relative risk.
Table 2 Effect sizes required for nonadherence interventions to have
acceptable value,* by baseline nonadherence and intervention cost. An
intervention is assumed to impact the relative risk (RR) of nonadherence.
An RR reduction of 1 means nonadherence is unchanged, and an RR of 0
means nonadherence is eliminated
Baseline
nonadherence
(% doses)
Duration of
intervention
Cost of
intervention ($)†
Smallest effect
with acceptable
value (largest RR)
20% One time 1,000 0.82
2,000 0.61
5,000 None
10,000 None
Persistent 1,000 0.87
2,000 0.75
5,000 0.32
10,000 None
50% One time 1,000 0.90
2,000 0.76
5,000 0.31
10,000 None
Persistent 1,000 0.93
2,000 0.87
5,000 0.66
10,000 0.25
*Acceptable value deﬁned as $100,000 per life-year.
†If intervention is recurrent, cost is yearly.
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nonadherence (50% of doses not taken as directed). Neverthe-
less, the minimum effect required varied, depending upon which
outcome metric was chosen. Using the metric of RR, patients
with severe nonadherence could obtain a favorable value with
interventions that had substantially smaller effects compared
with patients with moderate nonadherence, whereas using the
metric of ARR, patients with severe nonadherence could only
obtain a favorable value with interventions that had slightly
larger effects compared with patients with moderate nonadher-
ence. The substantial value of nonadherence interventions for
patients with moderate nonadherence may have great implica-
tions for HIV care because many patients in care have nonad-
herence in this range [1].
Our results underscore the potential beneﬁt for interventions
aimed at nonadherence risk factors (unhealthy alcohol use, drug
dependence, and depression), if these risk factors are indeed
causally related to nonadherence. For example, an intervention
to reduce unhealthy alcohol use that costs up to $2000 per year
may deliver acceptable value if it reduces unhealthy alcohol use
by RR  0.56 (ARR  0.44) for moderately nonadherent indi-
viduals and by RR  0.71 (ARR  0.29) for severely nonadher-
ent individuals (e.g., topiramate reduces heavy drinking days by
RR  0.48 compared with placebo and may fulﬁll these criteria
[26]). An intervention to reduce depression that costs up to
$2000 per year may deliver acceptable value if it reduces depres-
sion by RR  0.30 (ARR  0.70) for moderately nonadherent
Total cost
A
B
Other care costIntervention cost Drug cost
$250,000
$300,000
$350,000
Cost
$100,000
$150,000
$200,000
$0
$50,000
Total cost
Other care costIntervention cost Drug cost
$350,000
$400,000
$450,000
$500,000
Cost
$150,000
$200,000
$250,000
$300,000
$0
$50,000
$100,000
Figure 3 Proportional contributions of adherence
intervention costs, combination antiretroviral
therapy drug costs, and other costs to overall HIV
expenditures. Adherence interventions increase
expenditures not only because of the costs of the
interventions themselves, but also because of
increased drug costs, particularly if the interventions
are more effective (and therefore result in more
drug doses being consumed).The proportional con-
tribution of the nonadherence intervention remains
small if its cost is $1000 per year (A). For this
reason, its value would rise little even if its costs
were reduced further. In contrast, the proportional
contribution of a nonadherence intervention is large
if its cost is $10,000 per year (B). For this reason, its
value would rise substantially if its costs were
reduced further.
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individuals and by RR  0.47 (ARR  0.53) for severely non-
adherent individuals.
Our results were somewhat more pessimistic than the results
of Goldie et al. [3], who estimated that nonadherence interven-
tions costing as much as $12,000 per year may represent accept-
able value. In contrast, we found that interventions costing
$5000 per year or more were unlikely to represent acceptable
value, unless they had one-time costs and their effects persisted
indeﬁnitely. The main reason why our results are more pessimis-
tic is because we consider the increase in downstream costs that
result from increasing adherence. Patients who start to adhere
more use greater amounts of antiretroviral medications, and
these medications are often expensive, sometimes contributing
more to the incremental cost burden than the intervention itself.
Our study has notable limitations. We assumed that risk
behaviors only impact mortality through adherence, whereas
they may impact mortality in other ways (e.g., an effective inter-
vention for alcohol may reduce cirrhosis deaths, whereas an
effective intervention for drug dependence may reduce overdose
deaths). In our analyses, we assumed that behavioral risk factors
impacted life expectancy solely through their impact on antiret-
roviral adherence, and not through other health effects. We
assumed causal relationships between nonadherence and behav-
ioral risk factors, whereas the associations are based on obser-
vational studies that cannot demonstrate causality. The poorest
adherers often miss clinic visits and, therefore, are difﬁcult to
target with the types of interventions that we studied. Some of
our cost estimates date from the early era of highly active com-
bination ARV [3,11], yet their age is unlikely to undermine our
analysis because they reﬂect the current landscape of HIV costs
(e.g., reduced inpatient costs and increased drug costs) and
because ARV costs in the United States have changed relatively
little in real terms [27]. We assumed a willingness to pay for
health beneﬁts based on the society at large because data speciﬁc
to our particular populations (HIV and substance abuse) are
inadequate. Finally, our results may not apply to results from
pilot interventions, which often have high “start-up” costs that
could be amortized over longer time periods.
In conclusion, nonadherence interventions may represent
some of the “lowest hanging fruit” for improving HIV care and
have the advantage of not requiring any incremental technologi-
cal or scientiﬁc advances. Indeed, the promulgation of health
information technology and EMRs may have the collateral effect
of making it easier to identify patients with adherence problems
and to measure the success of interventions to help them. Our
results may inform the design of clinical trials of adherence
interventions because estimations of minimum acceptable effect
Table 3 Effect sizes required for unhealthy alcohol use interventions to
have acceptable value,* by baseline nonadherence level and intervention
cost. An intervention is assumed to impact the relative risk (RR) of
unhealthy alcohol use.An RR reduction of 1 means unhealthy alcohol use
is unchanged, and an RR of 0 means unhealthy alcohol use is eliminated
Baseline
nonadherence
(% doses)
Time course
of intervention
Cost of
intervention ($)†
Smallest effect
with acceptable
value (largest RR)‡
20% One time 1,000 0.73
2,000 0.42
5,000 None
10,000 None
Persistent 1,000 0.78
2,000 0.56
5,000 None
10,000 None
50% One time 1,000 0.74
2,000 0.53
5,000 None
10,000 None
Persistent 1,000 0.86
2,000 0.71
5,000 0.25
10,000 None
*Acceptable value deﬁned as $100,000 per life-year.
†If intervention is recurrent, cost is yearly.
‡Interventions with very small effect sizes (RR between 0.95 and 1) could not be evaluated
with certainty.
Table 4 Effect sizes required for drug dependence interventions to have
acceptable value,* by baseline nonadherence level and intervention cost.
An intervention is assumed to impact the relative risk (RR) of drug
dependence.An RR reduction of 1 means drug dependence is unchanged,
and an RR of 0 means drug dependence is eliminated
Baseline
nonadherence
(% doses)
Time course
of intervention
Cost of
intervention ($)†
Smallest effect
with acceptable
value (largest RR)‡
20% One time 1,000 0.72
2,000 0.35
5,000 None
10,000 None
Continuous 1,000 0.72
2,000 0.42
5,000 None
10,000 None
50% One time 1,000 0.59
2,000 0.33
5,000 None
10,000 None
Continuous 1,000 0.80
2,000 0.59
5,000 None
10,000 None
*Acceptable value deﬁned as $100,000 per life-year.
†If intervention is recurrent, cost is yearly.
‡Interventions with very small effect sizes (RR between 0.95 and 1) could not be evaluated
with certainty.
Table 5 Effect sizes required for depression interventions to have
acceptable value,* by baseline nonadherence level and intervention cost.
An intervention is assumed to impact the relative risk (RR) of depression.
An RR reduction of 1 means depression is unchanged, and an RR of 0
means depression is eliminated
Baseline
nonadherence
(% doses)
Time course
of intervention
Cost of
intervention ($)†
Smallest effect
with acceptable
value (largest RR)‡
20% One time 1,000 0.52
2,000 0.16
5,000 None
10,000 None
Continuous 1,000 0.65
2,000 0.30
5,000 None
10,000 None
50% One time 1,000 0.69
2,000 0.36
5,000 None
10,000 None
Continuous 1,000 0.73
2,000 0.47
5,000 None
10,000 None
*Acceptable value deﬁned as $100,000 per life-year.
†If intervention is recurrent, cost is yearly.
‡Interventions with very small effect sizes (RR between 0.95 and 1) could not be evaluated
with certainty.
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size may inform hypothesis speciﬁcation and statistical power
requirements. In addition, our results may inform resource allo-
cation decisions of organizations seeking to maximize quality of
care.
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